Ovid Therapeutics (OVID) Free Cash Flow Growth (3y) (2019 - 2026)

Ovid Therapeutics (OVID) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -5.05%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 31.07%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 14.71%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ovid Therapeutics 118.66 Mn -36.86 Mn - -4.65%

Historic Data

Download Data
DateValue
Mar 31, 2026 -4.65%
Dec 31, 2025 -3.73%
Sep 30, 2025 -0.34%
Jun 30, 2025 30.48%
Mar 31, 2025 20.05%
Dec 31, 2024 6.37%
Sep 30, 2024 -11.31%
Jun 30, 2024 9.60%
Mar 31, 2024 -28.14%
Dec 31, 2023 6.56%
Sep 30, 2023 -89.09%
Jun 30, 2023 12.06%
Mar 31, 2023 13.06%
Dec 31, 2022 18.13%
Sep 30, 2022 -10.17%
Jun 30, 2022 -6.59%
Mar 31, 2022 -16.05%
Dec 31, 2021 -3.53%
Sep 30, 2021 -3.16%
Jun 30, 2021 -18.13%